Please assess the completion status of the following clinical trial:

Trial Title: Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active (HBI \>10) refractory inflammatory and/or perianal fistulizing Crohn's disease who are prescribed infliximab as standard of care by their gastroenterologist.~Exclusion Criteria:~* Pregnant women.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remicade (Type: EXPERIMENTAL): Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).